/
GPCR
$51.69+$1.98 (+3.98%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$3.5B
71M shares
52-week range
$15.80 – $94.90
45% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
ADRC
Borrow rate
0.25%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$25.69
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $20.0K | $0 | $0 | $0 | $0 | $3.9M |
| Gross profit | −$20.0K | $0 | $0 | $0 | $0 | −$3.9M |
| Gross margin | — | — | — | — | — | — |
| R&D | $12.4M | $29.1M | $36.2M | $70.1M | $108.8M | $225.3M |
| Operating income | −$15.9M | −$37.7M | −$52.6M | −$102.8M | −$158.2M | −$287.6M |
| EBITDA | −$15.7M | −$37.6M | −$51.0M | −$75.7M | −$121.2M | −$136.8M |
| Net income | −$15.9M | −$40.0M | −$51.3M | −$89.6M | −$122.5M | −$141.2M |
| Net margin | — | — | — | — | — | — |
| EPS (diluted) | -0.45 | -1.20 | -1.44 | -2.43 | -2.34 | -2.40 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $38M | $-1.43 | $-1.68–$-1.25 | 10 |
| 2027 | $50000 | $-1.97 | $-2.51–$-1.70 | 9 |
| 2028 | $200M | $-1.63 | $-2.47–$1.11 | 8 |
| 2029 | $539M | $-0.29 | $-0.29–$-0.29 | 6 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$13.17
Price
$51.69
Implied downside
-75%
Peer comparison
Structure Therapeutics Inc. American Depositary Shares
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
www.structuretx.com- Employees
- 233
- IPO / List date
- Feb 3, 2023
- HQ
- SOUTH SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds GPCR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 55,800 | $2.7M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded GPCR yet.
